| 臺大學術典藏 |
2021-10-27T03:22:16Z |
PD-L1 expression in megakaryocytes and its clinicopathological features in primary myelofibrosis patients
|
Lee S.-H.; Lin C.-C.; Wei C.-H.; Chang K.-P.; CHANG-TSU YUAN; Tsai C.-H.; Liu J.-H.; Hou H.-A.; Tang J.-L.; Chou W.-C.; Tien H.-F. |
| 臺大學術典藏 |
2021-11-24T07:29:13Z |
PD-L1 expression in megakaryocytes and its clinicopathological features in primary myelofibrosis patients
|
Lee, Sze-Hwei; CHIEN-CHIN LIN; Wei, Chao-Hong; Chang, Ko-Ping; Yuan, Chang-Tsu; Tsai, Cheng-Hong; Liu, Jia-Hao; Hou, Hsin-An; Tang, Jih-Lu; Chou, Wen-Chien; Tien, Hwei-Fang |
| 臺大學術典藏 |
2022-01-25T05:25:46Z |
PD-L1 expression in megakaryocytes and its clinicopathological features in primary myelofibrosis patients
|
Lee, Sze-Hwei; Lin, Chien-Chin; Wei, Chao-Hong; Chang, Ko-Ping; Yuan, Chang-Tsu; Tsai, Cheng-Hong; Liu, Jia-Hao; Hou, Hsin-An; Tang, Jih-Lu; Chou, Wen-Chien; HWEI-FANG TIEN |
| 臺大學術典藏 |
2022-01-12T07:07:06Z |
PD-L1 expression in megakaryocytes and its clinicopathological features in primary myelofibrosis patients
|
Lee S.-H.; Lin C.-C.; Wei C.-H.; Chang K.-P.; Yuan C.-T.; Tsai C.-H.; Liu J.-H.; HSIN-AN HOU; Tang J.-L.; Chou W.-C.; Tien H.-F. |
| 臺大學術典藏 |
2022-08-12T08:07:48Z |
PD-L1 expression in megakaryocytes and its clinicopathological features in primary myelofibrosis patients
|
Lee S.-H.; Lin C.-C.; Wei C.-H.; Chang K.-P.; CHANG-TSU YUAN; Tsai C.-H.; Liu J.-H.; Hou H.-A.; Tang J.-L.; Chou W.-C.; Tien H.-F. |
| 臺大學術典藏 |
2022-02-14T23:55:52Z |
PD-L1 Expression in Monocytes Correlates with Bacterial Burden and Treatment Outcomes in Active Pulmonary Tuberculosis
|
Pan, Sheng Wei; CHIN-CHUNG SHU; Huang, Jhong Ru; Lee, Chang Ching; Tseng, Yen Han; Hung, Jung Jyh; Hsu, Po Kuei; Chen, Nien Jung; Su, Wei Juin; Feng, Jia Yih; Chen, Yuh Min |
| 國立臺灣大學 |
2015 |
PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy
|
Chang, Yih-Leong; Yang, Ching-Yao; Lin, Mong-Wei; Wu, Chen-Tu; Yang, Pan-Chyr; 吳振都; 張逸良; 楊泮池; 楊景堯; 林孟暐 |
| 臺大學術典藏 |
2020-02-20T02:56:58Z |
PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy
|
Chang Y.-L.; CHING-YAO YANG; Lin M.-W.; Wu C.-T.; Yang P.-C. |
| 臺大學術典藏 |
2020-03-06T05:26:12Z |
PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy
|
YIH-LEONG CHANG; Yang C.-Y.; Lin M.-W.; Wu C.-T.; Yang P.-C. |
| 臺大學術典藏 |
2020-03-07T06:56:23Z |
PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy
|
Lin M.-W.; Wu C.-T.; Yang P.-C.; Yang C.-Y.; YIH-LEONG CHANG; Yih-Leong Chang;Yang C.-Y.;Lin M.-W.;Wu C.-T.;Yang P.-C. |
| 臺大學術典藏 |
2015 |
PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy
|
Lin M.-W.; Wu C.-T.; Yang P.-C.; CHING-YAO YANG; Chang Y.-L. |
| 臺大學術典藏 |
2020-12-02T02:33:30Z |
PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy
|
Chang Y.-L.; Yang C.-Y.; Lin M.-W.; Wu C.-T.; Pan-Chyr Yang; Chang Y.-L.; Yang C.-Y.; Lin M.-W.; Wu C.-T.; PAN-CHYR YANG |
| 臺大學術典藏 |
2021-10-08T08:16:31Z |
PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy
|
Chang Y.-L.; Yang C.-Y.; MONG-WEI LIN; Wu C.-T.; Yang P.-C. |
| 臺大學術典藏 |
2022-03-04T05:33:34Z |
PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy
|
Chang Y.-L.; Yang C.-Y.; Lin M.-W.; CHEN-TU WU; Yang P.-C. |
| 臺大學術典藏 |
2018-09-10T15:27:10Z |
PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy.
|
Chang, Yih-Leong;Yang, Ching-Yao;Lin, Mong-Wei;Wu, Chen-Tu;Yang, Pan-Chyr; Yih-Leong Chang, Ching-Yao Yang, Mong-Wei Lin, Chen-Tu Wu, Pan-Chyr Yang; 吳振都;張逸良;楊泮池;楊景堯;林孟暐; Chang, Yih-Leong; CHING-YAO YANG; CHEN-TU WU; Yang, Ching-Yao; Lin, Mong-Wei; YIH-LEONG CHANG; Wu, Chen-Tu; Yang, Pan-Chyr |
| 臺大學術典藏 |
2022-09-06T01:55:22Z |
PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients
|
Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; Su, Kang-Yi; SUNG-LIANG YU; Chen, Jeremy J W; Huang, Yen-Hsiang; Chang, Gee-Chen |
| 國家衛生研究院 |
2020-11-03 |
PD-L1/PD-1 blockade in breast cancer: The immunotherapy era (Review)
|
Li, CJ;Lin, LT;Hou, MF;Chu, PY |
| 國立成功大學 |
2019 |
PD-L1不只是Biomarker！探討肺癌細胞本身的PD-L1促進轉移的機轉，及其與TIP60-mediated 癌症EMT的相關性
|
蘇文彬 |
| 國立成功大學 |
2018 |
PD-L1不只是Biomarker！探討肺癌細胞本身的PD-L1促進轉移的機轉，及其與TIP60-mediated 癌症EMT的相關性
|
蘇文彬 |
| 國家衛生研究院 |
2008 |
PD-L1在小鼠自體免疫性糖尿病動物模式之幹細胞治療所扮演的角色
|
顏伶汝;司徒惠康 |
| 國家衛生研究院 |
2010 |
PD-L1在小鼠自體免疫性糖尿病動物模式之幹細胞治療所扮演的角色
|
顏伶汝;司徒惠康 |
| 國家衛生研究院 |
2009 |
PD-L1在小鼠自體免疫性糖尿病動物模式之幹細胞治療所扮演的角色
|
顏伶汝;司徒惠康 |
| 國立成功大學 |
2016 |
PD-L1在肺癌的探索及其治療應用—與 mTOR inhibitor，DNA damage agents及DNA修補蛋白MORF 的相關性
|
蘇文彬 |
| 國立成功大學 |
2006-04 |
Pd-oxide-Al0.24Ga0.76As (MOS) high electron mobility transistor (HEMT)-based hydrogen sensor
|
Cheng, Chin-Chuan; Tsai, Yan-Ying; Lin, Kun-Wei; Chen, Huey-Ing; Hsu, Wei-Hsi; Hung, Ching-Wen; Liu, Rong-Chau; Liu, Wen-Chau |
| 國立交通大學 |
2017-04-21T06:49:36Z |
PD-SOI MOSFET Body-to-Body Leakage Scaling Trend and Optimization
|
Lo, H. C.; Luo, W. C.; Lu, W. Y.; Cheng, C. F.; Wu, Benny; Chen, T. L.; Lien, C. H.; Fung, Samuel K. H.; Tuan, H. C. |
